Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK
Open accessAbstract
Aims: Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are appealing as glucose‐lowering therapy for individuals with type 2 diabetes mellitus (T2DM) as they also reduce body weight and are associated with low rates of hypoglycaemia. This analysis assessed the long‐term cost‐effectiveness of semaglutide 0.5 and 1 mg vs dulaglutide 1.5 mg (two once‐weekly GLP‐1 receptor agonists) from a UK healthcare payer perspective, based on the head‐to‐head SUSTAIN 7 trial, to inform healthcare decision making. Materials and Methods: Long‐term outcomes were projected using the IQVIA CORE Diabetes Model (version 9.0). Baseline cohort characteristics, changes in physiological parameters and adverse event rates were derived from the 40‐week SUSTAIN 7 trial. Costs to a healthcare payer were assessed, and these captured pharmacy costs and costs of complications. Utilities were taken from published sources. Results: Once‐weekly semaglutide 0.5 and 1 mg were associated with improvements in quality‐adjusted life expectancy of 0.04 and 0.10 quality‐adjusted life years, respectively, compared with dulaglutide 1.5 mg. Clinical benefits were achieved at reduced costs, with lifetime cost savings of GBP 35 with once‐weekly semaglutide 0.5 mg and GBP 106 with the once‐weekly semaglutide 1 mg, resulting from fewer diabetes‐related complications due to better glycaemic control. Therefore, both doses of once‐weekly semaglutide were considered dominant vs dulaglutide 1.5 mg (improving outcomes and reducing costs). Conclusions: Compared with treatment with dulaglutide, once‐weekly semaglutide represents a cost‐effective option for treating individuals in the UK with T2DM who are not achieving glycaemic control with metformin, projected to both improve clinical outcomes and reduce costs.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In type 2 diabetes, several studies have found absolute cost savings and cost-effectiveness for semaglutide 1.0 mg relative to other diabetes drugs.
“Several studies in patients with type 2 diabetes (in different countries) have shown absolute cost savings with semaglutide 1.0 mg, as well as the cost effectiveness of semaglutide 1.0 mg compared to other diabetes pharmacotherapies.(58, 59)”
From Semaglutide for the treatment of obesity (2023) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419 · see citing works
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · see citing works
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397 · see citing works
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1× · see citing works
“Once-weekly semaglutide was associated with a significantly lower risk of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke compared with placebo plus standard of care.(56) The REWIND study (NCT01394952) to assess the impact of dulaglutide on cardiovascular risk has not yet been reported.”
BackgroundSelf-citationStearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 4,803 · see citing works
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,489 · see citing works
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · see citing works
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081 · see citing works
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428 · see citing works
Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration
UK Hypoglycaemia Study Group (2007) · Diabetologia · doi:10.1007/s00125-007-0599-y · Cited by 825 · see citing works
Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790 · see citing works
Self-citationInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M. A., Peters, A. L., Τσάπας, Α., Wender, R. C., & Matthews, D. R. (2015) · Diabetologia · doi:10.1007/s00125-014-3460-0 · Cited by 695 · see citing works
Clarke, P. M., Gray, A. M., Briggs, A., Farmer, A. J., Fenn, P., Stevens, R. J., Matthews, D. R., Stratton, I. M., Holman, R. R., & on behalf of the UK Prospective Diabetes Study (UKPDS) Group (2004) · Diabetologia · doi:10.1007/s00125-004-1527-z · Cited by 615 · see citing works
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596 · see citing works
Wolff, L. F., Smith, Q. T., Snyder, W. K., Bedrick, J. A., Liljemark, W. F., Aeppli, D. M., & Bandt, C. L. (1988) · Journal Of Clinical Periodontology · doi:10.1111/j.1600-051x.1988.tb01003.x · Cited by 577 · see citing works
Palmer, A. J., Roze, S., Valentine, W. J., Minshall, M. E., FOOS, V., Lurati, F. M., Lammert, M., & Spinas, G. A. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x1980 · Cited by 523 · see citing works
Ahrén, B., Masmiquel, L., Kumar, H., Sargin, M., Karsbøl, J. D., Jacobsen, S. H., & Chow, F. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30092-x · Cited by 495 · cited 3× · see citing works
“indicate that patients should be routinely assessed and their therapy should be modified and their treatment goals revised accordingly.(13,58)”
BackgroundStettler, C., Allemann, S., Jüni, P., Cull, C. A., Holman, R. R., Egger, M., Krähenbühl, S., & Diem, P. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.09.015 · Cited by 468 · see citing works
Aroda, V. R., Bain, S. C., Cariou, B., Piletič, M., Rose, L., Axelsen, M., Rowe, E., & DeVries, J. H. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30085-2 · Cited by 464 · see citing works
Self-citationGriffin, S. J., Borch-Johnsen, K., Davies, M. J., Khunti, K., Rutten, G. E., Sandbæk, A., Sharp, S. J., Simmons, R. K., van den Donk, M., Wareham, N. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60698-3 · Cited by 462 · see citing works
Validation of the CORE Diabetes Model Against Epidemiological and Clinical Studies
Palmer, A. J., Rozea, S., Valentinea, W. J., Minshallb, M. E., Foosa, V., Luratia, F. M., Lammerta, M., & Spinasc, G. A. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x2006 · Cited by 283 · see citing works
Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes
Currie, C. J., Morgan, C. L., Poole, C., Sharplin, P., Lammert, M., & McEwan, P. C. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x115757 · Cited by 278 · see citing works
Guidelines for Computer Modeling of Diabetes and Its Complications
American Diabetes Association Consensus Panel (2004) · Diabetes Care · doi:10.2337/diacare.27.9.2262 · Cited by 270 · see citing works
Review of Utility Values for Economic Modeling in Type 2 Diabetes
Beaudet, A., Clegg, J., Thuresson, P.-O., Lloyd, A., & McEwan, P. C. (2014) · Value in Health · doi:10.1016/j.jval.2014.03.003 · Cited by 256 · see citing works
Validation of the IMS CORE Diabetes Model
McEwan, P. C., FOOS, V., Palmer, J. L., Lamotte, M., Lloyd, A., & Grant, D. J. W. (2014) · Value in Health · doi:10.1016/j.jval.2014.07.007 · Cited by 236 · see citing works
Alva, M. L., Gray, A. M., Mihaylova, B., Leal, J., & Holman, R. R. (2014) · Diabetic Medicine · doi:10.1111/dme.12647 · Cited by 191 · see citing works
Evans, M., Khunti, K. K., Mamdani, M., Galbo-Jørgensen, C. B., Gundgaard, J., Bøgelund, M., & Harris, S. B. (2013) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-11-90 · Cited by 168 · see citing works
Bradbury, A. W., Adam, D. J., Bell, J., Jf, F., Fowkes, F. G. R., Gillespie, I., RAAB, G. M., & Ruckley, C. (2010) · Health Technology Assessment · doi:10.3310/hta14140 · Cited by 167 · see citing works
Costs of managing severe hypoglycaemia in three European countries
Hammer, M., Lammert, M., Mejías, S. M., Kern, W., & Frier, B. M. (2009) · Journal of Medical Economics · doi:10.3111/13696990903336597 · Cited by 151 · see citing works
Kent, S., Schlackow, I., Lozano-Kühne, J., Reith, C. A., Emberson, J., Haynes, R., Gray, A. M., Cass, A., Baigent, C., Landray, M., et al. (2015) · BMC Nephrology · doi:10.1186/s12882-015-0054-0 · Cited by 125 · see citing works
Cross-trimester repeated measures testing for Down’s syndrome screening: an assessment
Wright, D., Bradbury, I., Malone, F. D., D’Alton, M. E., Summers, A. M., Huang, T., Ball, S., Baker, A., Nix, B., Aitken, D. A., et al. (2010) · Health Technology Assessment · doi:10.3310/hta14330 · Cited by 90 · see citing works
Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries
Ghatnekar, O., Willis, M. S., & Persson, U. (2002) · Journal of Wound Care · doi:10.12968/jowc.2002.11.2.26675 · Cited by 87 · see citing works
Cassar, K. (2006) · BMJ · doi:10.1136/bmj.39001.562813.de · Cited by 54 · see citing works
Witkowski, M., Wilkinson, L., Webb, N., Weids, A., Glah, D. R., & Vražić, H. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0424-2 · Cited by 45 · see citing works
Sharma, R., Wilkinson, L., Vražić, H., Popoff, E., Lopes, S. H. K., Kanters, S., & Druyts, E. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1476332 · Cited by 31 · see citing works
O’Reilly, D. J., Hopkins, R. B., Blackhouse, G., Clarke, P., Hux, J. E., Tarride, J., Dolovich, L. R., & Goeree, R. A. (2007) · Canadian Journal of Diabetes · doi:10.1016/s1499-2671(07)13007-0 · Cited by 27 · see citing works
Hunt, B., Kragh, N., McConnachie, C. C., Valentine, W. J., Rossi, M. C., & Montagnoli, R. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.05.354 · Cited by 24 · see citing works
Self-citationLiraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis
Lorenzi, M. F., Ploug, U. J., Langer, J., Skovgaard, R., Zoratti, M. J., & Jansen, J. P. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0217-4 · Cited by 20 · see citing works
Hunt, B., Vega-Hernandez, G., Valentine, W. J., & Kragh, N. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12890 · Cited by 20 · see citing works
Self-citationMezquita‐Raya, P., de Arellano, A. R., Kragh, N., Vega-Hernandez, G., Pöhlmann, J., Valentine, W. J., & Hunt, B. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0239-6 · Cited by 18 · see citing works
Self-citationThe Cost of Non-Severe Hypoglycaemia In Europe
Chubb, B., & Tikkanen, C. K. (2015) · Value in Health · doi:10.1016/j.jval.2015.09.2118 · Cited by 15 · see citing works
Semaglutide Reduces HbA1c Across Baseline HbA1c Subgroups Across SUSTAIN 1–5 Clinical Trials
Tsoukas, G. M., Bain, S. C., Araki, E., Desouza, C. V., Garg, S. K., Rose, L., Bergan, E. Q., Karsbøl, J. D., & DeVries, H. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.08.132 · Cited by 10 · see citing works
Self-citationSemaglutide Reduces Body Weight Across Baseline BMI Subgroups Across SUSTAIN 1–5
Leiter, L. A., Charpentier, G., CHAYKIN, L. B., Garvey, W. T., Warren, M., Karsbøl, J. D., Thielke, D., & Masmiquel, L. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.08.020 · Cited by 8 · see citing works
Semaglutide Reduces Body Weight vs. Dulaglutide across Baseline BMI Subgroups in SUSTAIN 7
Viljoen, A., Blüher, M., Chow, F. C. C., le Roux, C. W., Rosenstock, J., Lausvig, N. L., YILDIRIM, E., & Lingvay, I. (2018) · Diabetes · doi:10.2337/db18-1083-p · Cited by 8 · see citing works
Self-citationCost of Type 2 Diabetes Management And Associated Complications In The United Kingdom
Rtveladze, K., & Hoxer, C. (2017) · Value in Health · doi:10.1016/j.jval.2017.08.444 · Cited by 6 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 3
- [6]National Institute for Health and Care Excellence. Type 2 diabetes in adults: management (NG28). 2015 https://www.nice.org.uk/guidance/ng28/resources/type-2-diabetes-in-adults-management-pdf-1837338615493. Accessed December 12, 2017. 26741015
- [42]O'Reilly D, Hopkins R, Blackhouse G, Clarke P, Hux J, Guan J. Development of an Ontario Diabetes Economic Model (ODEM) and application to a multidisciplinary primary care diabetes management program. Programs for Assessment of Technology in Health; 2007 https://books.google.ch/books/about/Development_of_an_Ontario_Diabetes_Econo.html?id=X_lGAQAACAAJ&redir_esc=y
- [49]National Institute for Health and Care Excellence. Neuropathic pain in adults: pharmacological management in nonspecialist settings. NICE guideline (CG173). 2013 www.nice.org.uk/guidance/cg173. Accessed December 12, 2017. 33180400
Cited by
Sorted by citations
Semaglutide for the treatment of obesity
Chao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.12.008 · Cited by 227 · see citing works
Ruan, Z., Yang, L., Shi, H., Yue, X., Wang, Y., Liang, M., & Hu, H. (2021) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2021.1860022 · Cited by 15 · see citing works
Liu, L., Ruan, Z., Ung, C. O. L., Zhang, Y., Shen, Y., Han, S., Jia, R., Qiao, J., Hu, H., & Guo, L. (2023) · Diabetes Therapy · doi:10.1007/s13300-022-01336-7 · Cited by 12 · see citing works
- Authors
- Viljoen, A., Hoxer, C. S., Johansen, P., Malkin, S., Hunt, B., & Bain, S. C.
- Affiliations
- Lister Hospital (GB)
- Novo Nordisk (United Kingdom) (GB)
- Novo Nordisk (Denmark) (DK)
- Ossian Health Economics and Communications Basel Switzerland
- Swansea University (GB)
- Corresponding author
- Hunt, Barnaby
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2018-11-28
- Volume
- 21
- Issue
- 3
- Pages
- 611-621
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- PMC
- PMC6587509
- OpenAlex
- W2898542079
- Cited by
- 45
- References
- 47
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 4 · 2023: 5 · 2022: 9 · 2021: 5 · 2020: 7 · 2019: 8
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Obesity and Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- semaglutide, dulaglutide, type 2 diabetes, GLP-1 receptor agonists, cost-effectiveness, quality-adjusted life years, diabetes complications, glycemic control, metformin failure
- MeSH terms
- Semaglutide, Clinical Trials as Topic, Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Drug Administration Schedule, Glucagon-Like Peptides, United Kingdom, Health Resources, Humans, Immunoglobulin Fc Fragments, Recombinant Fusion Proteins, Time Factors, Health Care Costs, Models, Economic, Quality-Adjusted Life Years, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
